UNSPSC 51172148: Rociverine

This classification denotes an antispasmotic agent with the molecular formula C20H37NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VI08KS44V0, chemically known as (1,1-bicyclohexyl)-2-carboxylic acid, 1-hydroxy-, 2-(diethylamino)-1-methylethyl ester but generally known as rociverine, which bears US NIH Compound Identifier 68705. European Medicines Agency schedules Rociverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10352MIG.

UNSPSC 51172148 Rociverine is a Commodity code that covers pharmaceutical and chemical substances used in clinical and forensic testing. State and local governments procure rociverine primarily as a reagent or component in drug-screening and confirmatory testing protocols, particularly in criminal-justice and offender-supervision contexts. The code appears in solicitations for specimen collection and drug-testing services where reagents and testing methodologies are integral to the service delivery. Issuing bodies under this code include county departments of community supervision and corrections, which contract for offender drug testing as part of probation and community-based correctional oversight. The service model typically encompasses staffing collection sites, operating randomized testing notifications, and performing immunoassay screening with confirmatory analysis (LC/MS/MS or GC/MS), all of which depend on specific reagent supplies including rociverine and related compounds. Vendors must maintain SAMHSA, state, or CAP laboratory certification to handle these materials and perform the testing.

Collin County, Texas, posted the most recent relevant opportunity on September 25, 2026 under RFP 2026-327, seeking offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years (commencing September 1, 2026, with three optional one-year renewals). The RFP called for staffing two collection sites in Plano and McKinney during business hours plus five Saturdays annually, operating an Interactive Voice Response system for randomized notifications, and performing approximately 25,031 annual tests (5,452 five-panel screens and 18,006 six-panel screens) with ancillary testing using multiple methodologies including oral fluid and hair testing. Proposals were due July 23, 2026 at 2:00 p.m., and the anticipated award date was August 10, 2026. Evaluation weighted vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews worth up to 30 points. Pricing was submitted on a per-test basis with three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), and all costs including freight, delivery, insurance, and staffing had to be included with no additional surcharges permitted.